Last reviewed · How we verify
GSK investigational vaccine GSK2340272A
GSK investigational vaccine GSK2340272A is a Vaccine Biologic drug developed by GlaxoSmithKline. It is currently in Phase 3 development.
GSK2340272A is an investigational vaccine designed to stimulate immune responses against specific disease targets through antigen presentation and T-cell activation.
At a glance
| Generic name | GSK investigational vaccine GSK2340272A |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
As a vaccine candidate, GSK2340272A works by presenting antigens to the immune system to generate both humoral (antibody) and cellular (T-cell) immune responses. The vaccine formulation likely includes adjuvants or delivery systems to enhance immunogenicity and protective immunity against its target pathogen or disease.
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults (PHASE3)
- Immunogenicity and Safety Study of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in Adults (PHASE3)
- Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children (PHASE3)
- Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults (PHASE3)
- Study to Evaluate Immunogenicity & Safety of an Investigational Influenza Vaccine in Adults (PHASE3)
- Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children (PHASE2)
- Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in Adults, Using Two Different Manufacturing Processes (PHASE3)
- Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK investigational vaccine GSK2340272A CI brief — competitive landscape report
- GSK investigational vaccine GSK2340272A updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about GSK investigational vaccine GSK2340272A
What is GSK investigational vaccine GSK2340272A?
How does GSK investigational vaccine GSK2340272A work?
Who makes GSK investigational vaccine GSK2340272A?
What drug class is GSK investigational vaccine GSK2340272A in?
What development phase is GSK investigational vaccine GSK2340272A in?
Related
- Drug class: All Vaccine drugs
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Immunology
- Compare: GSK investigational vaccine GSK2340272A vs similar drugs
- Pricing: GSK investigational vaccine GSK2340272A cost, discount & access